Adaptimmune Therapeutics plc (ADAP) - חוב להון עצמי

The price history on the Adaptimmune (ADAP) chart demonstrates a debt-to-equity ratio of 0.00, highlighting a dependence on a single technological platform that is offset by grants and initial licenses. The business relies on patents in the field of T-cell therapy for solid tumors to ensure multi-year profits. Adaptimmune is implementing TCR approaches, reprogramming immunity to fight cancer and update oncological standards.

This ratio is calculated as the proportion of total debt to net equity, measuring the company's dependence on external financing and its level of financial leverage. For Adaptimmune (ADAP), whose cell immunotherapy development is not subject to market cyclicality, the ratio of total liabilities to shareholders' equity reflects the stability of long-term partnerships and the business's ability to scale vital technologies without the risk of default.